Searched for
INDIAN PHARMACEUTICAL MARKET
As we look to the next decade, I hope in the future we can further grow in generics as we transition into drug innovation: Aman Mehta, MD, Torrent PharmaceuticalsTorrent Pharma aims to become a top three Indian drug maker. The company is transitioning from generics to drug innovation for growth. Aman...- ChrysCapital acquires controlling 70.68% stake in Novartis India listed unit in first majority pharma investmentChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical...
- TVS Motor Company among 9 stocks to hit 52-week highs & rally up to 15% in a monthNine BSE 100 stocks scaled fresh 52-week highs despite the Sensex slipping 70 points on Tuesday. Bajaj Auto, Titan, TVS Motor and Divi's La...
- Alembic Pharma gets USFDA approval for generic chronic constipation treatment tabletsAlembic Pharmaceuticals announced USFDA approval for its generic prucalopride tablets. The company received final approval for strengths of...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Pharma mutual funds top return charts across horizons. Should investors chase the rally or stay cautious?Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outper...
- US tariff proposal wake-up call for Indian pharma to diversify, innovate: ExpertsUS pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market...
- Trump’s 10% tariff blow that could work in India’s favourThe US Section 301 tariff has escalated cost challenges for Indian exporters, but it simultaneously provides a unique advantage. Competing ...
- Pharma deal activity hits four-quarter low, but mega Sun Pharma acquisition drives valueIndia's pharma and healthcare sector recorded 65 deals worth $13.9 billion in Q2 CY2026, with volumes falling 17% quarter-on-quarter to a f...
- India sends 4.5 tonnes of medical aid to Kenya to boost Ebola preparednessIndia has delivered essential medical supplies to Kenya for disease preparedness. This assistance strengthens Kenya's capacity to respond t...
- Tariffs alone will not produce sustainable generic medicine in US: IPAThe Indian Pharmaceutical Alliance believes tariffs alone will not build US generic drug manufacturing. Broader reforms are needed for fair...
- Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investorsDonald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analys...
- Indian pharma firms may yet survive Trump's 200% tariff bombshellDonald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...
- 200% Trump tariff shock? India’s cheap pills may still beat US rivalsUS President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...
- Trump’s 100% generic drug duty threatens US low-cost supplyPresident Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028...
- Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% stormTrump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...
- Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one...
- Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...
- Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...
- Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bnAlembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug...
Load More
